Cresset Asset Management LLC trimmed its holdings in shares of ARK Genomic Revolution ETF (BATS:ARKG – Free Report) by 15.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 20,130 shares of the company’s stock after selling 3,696 shares during the period. Cresset Asset Management LLC’s holdings in ARK Genomic Revolution ETF were worth $474,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also modified their holdings of ARKG. Atria Wealth Solutions Inc. increased its holdings in ARK Genomic Revolution ETF by 121.1% in the fourth quarter. Atria Wealth Solutions Inc. now owns 19,792 shares of the company’s stock valued at $466,000 after buying an additional 10,841 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in shares of ARK Genomic Revolution ETF in the 4th quarter worth approximately $401,000. Raymond James Financial Inc. purchased a new position in ARK Genomic Revolution ETF in the 4th quarter valued at approximately $2,027,000. Barclays PLC raised its holdings in ARK Genomic Revolution ETF by 252.7% during the third quarter. Barclays PLC now owns 285,108 shares of the company’s stock worth $7,299,000 after purchasing an additional 204,283 shares during the last quarter. Finally, Whipplewood Advisors LLC purchased a new stake in ARK Genomic Revolution ETF during the fourth quarter worth $305,000.
ARK Genomic Revolution ETF Price Performance
ARK Genomic Revolution ETF stock opened at $21.49 on Thursday. ARK Genomic Revolution ETF has a fifty-two week low of $17.51 and a fifty-two week high of $31.16. The stock’s fifty day moving average is $21.51 and its two-hundred day moving average is $24.03.
ARK Genomic Revolution ETF Company Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Featured Articles
- Five stocks we like better than ARK Genomic Revolution ETF
- What is the Australian Securities Exchange (ASX)
- SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start
- What Investors Need to Know to Beat the Market
- AMD’s AI-Powered Stock Price Rally Just Shifted Gears
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
